<DOC>
	<DOC>NCT00685399</DOC>
	<brief_summary>This study will test the efficacy and safety of AIN457 for patients with active uveitis that requires systemic immunosuppression.</brief_summary>
	<brief_title>Safety and Efficacy of AIN457 in Noninfectious Uveitis</brief_title>
	<detailed_description />
	<mesh_term>Uveitis</mesh_term>
	<criteria>Inclusion criteria: Active uveitis (i.e., uveitis that is not in remission). Intermediate uveitis, posterior uveitis, or panuveitis must be sufficiently severe that systemic immunosuppression is indicated. Exclusion criteria: Active infection. Weight must not be greater that 120kg. Other protocoldefined inclusion/exclusion criteria may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>November 2013</verification_date>
	<keyword>Uveitis,</keyword>
	<keyword>eye,</keyword>
	<keyword>IL-17,</keyword>
	<keyword>IL-17A,</keyword>
	<keyword>IL17,</keyword>
	<keyword>AIN457,</keyword>
	<keyword>Vogt-Koyanagi-Harada,</keyword>
	<keyword>Behcet's,</keyword>
	<keyword>Behcet,</keyword>
	<keyword>Sympathetic ophthalmia,</keyword>
	<keyword>Multifocal choroiditis,</keyword>
	<keyword>Birdshot,</keyword>
	<keyword>HLA-B27,</keyword>
	<keyword>Birdshot retinochoroiditis,</keyword>
	<keyword>Retinal vasculitis,</keyword>
	<keyword>Sarcoidosis,</keyword>
	<keyword>Intermediate uveitis,</keyword>
	<keyword>Panuveitis,</keyword>
	<keyword>Posterior uveitis</keyword>
</DOC>